Accessibility

Our global life sciences company brings diagnostic testing & drug development together.

Labcorp.com

SNP Microarray−Oncology (Reveal®)

CPT: 81277
Updated on 08/31/2021
Print Share

Synonyms

  • Reveal® Microarray

Special Instructions

Pertinent medical findings should accompany the test request form.


Expected Turnaround Time

14 days

10 - 14 days

14 days14 days




Specimen Requirements


Specimen

Whole blood, bone marrow, or nonfixed tumor tissue


Volume

4 mL whole blood, 2 mL bone marrow, or >2 to 4 mm3 tissue


Minimum Volume

2 mL whole blood or 1 mL bone marrow for array only (Note: This volume does not allow for repeat testing.)


Container

Green-top (heparin) tube (preferred), yellow-top (ACD) tube, or lavender-top (EDTA) tube; sterile container containing sterile saline, Ringer's lactate, or Hanks' balanced salt solution or transport medium provided by the cytogenetic laboratory


Storage Instructions

Maintain specimen at room temperature.


Causes for Rejection

Quantity not sufficient for analysis; gel-separator tubes; microtainer tubes; fixed cell pellets

Quantity not sufficient for analysis; gel-separator tubes; microtainer tubes; fixed cell pellets

Quantity not sufficient for analysis; gel-separator tubes; microtainer tubes; fixed cell pellets

Quantity not sufficient for analysis; gel-separator tubes; microtainer tubes; fixed cell pellets

Quantity not sufficient for analysis; gel-separator tubes; microtainer tubes; fixed cell pellets


Test Details


Use

This test will detect chromosomal imbalance that may be present in neoplastic disorders and clonal evolution. It provides detection of copy-neutral loss of heterozygosity of any chromosome, and the percent and location of homozygosity, that may be associated with cancer gene mutations.

This test will detect chromosomal imbalance that may be present in neoplastic disorders and clonal evolution. It provides detection of copy-neutral loss of heterozygosity of any chromosome, and the percent and location of homozygosity, that may be associated with cancer gene mutations.

This test will detect chromosomal imbalance that may be present in neoplastic disorders and clonal evolution. It provides detection of copy-neutral loss of heterozygosity of any chromosome, and the percent and location of homozygosity, that may be associated with cancer gene mutations.

This test will detect chromosomal imbalance that may be present in neoplastic disorders and clonal evolution. It provides detection of copy-neutral loss of heterozygosity of any chromosome, and the percent and location of homozygosity, that may be associated with cancer gene mutations.

This test will detect chromosomal imbalance that may be present in neoplastic disorders and clonal evolution. It provides detection of copy-neutral loss of heterozygosity of any chromosome, and the percent and location of homozygosity, that may be associated with cancer gene mutations.


Limitations

This SNP assay does not detect balanced rearrangements, low-level mosaicism (<10%), marker chromosomes that only that only contain heterochromatin or tetraploidy.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

This SNP assay does not detect balanced rearrangements, low-level mosaicism (<10%), marker chromosomes that only that only contain heterochromatin or tetraploidy.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

This SNP assay does not detect balanced rearrangements, low-level mosaicism (<10%), marker chromosomes that only that only contain heterochromatin or tetraploidy.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

This SNP assay does not detect balanced rearrangements, low-level mosaicism (<10%), marker chromosomes that only that only contain heterochromatin or tetraploidy.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

This SNP assay does not detect balanced rearrangements, low-level mosaicism (<10%), marker chromosomes that only that only contain heterochromatin or tetraploidy.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.


Methodology

SNP microarray analysis is performed using the Cytoscan® HD platform, which uses more than 743,000 SNP probes and 1,953,000 NPCN probes with a median spacing of 0.88 kb.

SNP microarray analysis is performed using the Cytoscan® HD platform, which uses more than 743,000 SNP probes and 1,953,000 NPCN probes with a median spacing of 0.88 kb.

SNP microarray analysis is performed using the Cytoscan® HD platform, which uses more than 743,000 SNP probes and 1,953,000 NPCN probes with a median spacing of 0.88 kb.

SNP microarray analysis is performed using the Cytoscan® HD platform, which uses more than 743,000 SNP probes and 1,953,000 NPCN probes with a median spacing of 0.88 kb.

SNP microarray analysis is performed using the Cytoscan® HD platform, which uses more than 743,000 SNP probes and 1,953,000 NPCN probes with a median spacing of 0.88 kb.


References

Gunnarsson R, Staaf J, Jansson M, et al. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia−A comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer. 2008 Aug; 47(8):697-711.18484635

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
510146 Reveal (R) SNP CMA - Oncology 510139 Specimen Type 31208-2
510146 Reveal (R) SNP CMA - Oncology 510147 # of Genotyping Targets N/A
510146 Reveal (R) SNP CMA - Oncology 510218 Diagnosis 62357-9
510146 Reveal (R) SNP CMA - Oncology 510159 Interpretation 62365-2
510146 Reveal (R) SNP CMA - Oncology 510161 Director Review: 48672-0
510146 Reveal (R) SNP CMA - Oncology 512123 PDF 51967-8

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf